
09-830/MM Buch

=> d 15 que stat;d 1-2 ide cbib abs L3 STR



VAR G1=O/S
REP G2=(0-3) A
VAR G3=H/ME
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L5 2 SEA FILE=REGISTRY SSS FUL L3

100.0% PROCESSED 677 ITERATIONS

SEARCH TIME: 00.00.06

2 ANSWERS

L5 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2001 ACS

RN 259254-59-6 REGISTRY

CN 2-Propenoic acid, 3-[4-[1,3-bis(bicyclo[2.2.1]hept-2-ylmethyl)-2,3,6,7-tetrahydro-2,6-dioxo-1H-purin-8-yl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH

MF C30 H34 N4 O4

SR CA

LC STN Files: CA, CAPLUS

Double bond geometry as shown.

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:180589 Preparation of phenylxanthine derivatives as cell adhesion inhibitors.. Daluge, Susan Mary; Jurgensen, Cynthia Holder; Martin, Michael Tolar; Osterhout, Martin Howard (Glaxo Group Limited,

UK).

PCT Int. Appl. WO 2000009507 Al 20000224, 101 pp. DESIGNATED STATES: W:
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF,
BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU,
MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
APPLICATION: WO 1999-EP5814 19990811. PRIORITY: GB 1998-17623 19980813.

GΙ

$$\begin{array}{c|c} & & & & & & & \\ R^4 \, (\text{CH}_2) \, _{q1} & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ R^7 & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & &$$

Title compds. [I; Z = 5-6 membered (substituted) (heteroatom-contg.) cycloalkyl, aryl; R1 = H, Me; R2 = H, alkyl, aryl, aralkyl; m = 0, 1; n = 1-50; X = O, imino, CH2O, CH2NH, etc.; Q = (CH2)p, (CH:CH)p, (C.tplbond.C)p, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, aminoalkyl; R4, R5 = H, cycloalkyl, alkyl, alkenyl, (substituted) aryl, heterocyclyl; R6, R7 = O, S; q, q1 = 0-10; with provisos], were prepd. Thus, (E)-4-[1,3-bis(benzyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl]cinnamic acid (prepn. given) in DMF was heated to near reflux and treated with carbonyldiimidazole followed by stirring for 18 h to give

(E)-1,3-bis(benzyl)-8-[3-[2-(1H-imidazol-1-ylcarbonyl)vinyl]phenyl]-9H-purin-2,6(1H,3H)-dione. The latter was refluxed 20 h with nonaethylene glycol monomethyl ether and K2CO3 in MeCN to give 59% (E)-4-[1,3-bis(benzyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl]cinnamic acid nonaethylene glycol Me ether ester. I inhibited adhesion of leukocytes

to endothelial cell monolayers with IC50's of <0.1 nM to >1000 nM.

- L5 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2001 ACS
- RN 259254-58-5 REGISTRY
- CN 2-Propenoic acid, 3-[4-[1,3-bis(bicyclo[2.2.1]hept-2-ylmethyl)-2,3,6,7-tetrahydro-2,6-dioxo-1H-purin-8-yl]phenyl]-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester, (2E)- (9CI) (CA INDEX NAME)
- FS STEREOSEARCH
- MF C49 H72 N4 O13
- SR CA
- LC STN Files: CA, CAPLUS

Double bond geometry as shown.

PAGE 1-A

PAGE 1-B

PAGE 1-C

_ OMe

Page 3

Prepared by M. Hale 308-4258

1 REFERENCES IN FILE CA (1967 TO DATE) 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 132:180589 Preparation of phenylxanthine derivatives as cell adhesion inhibitors.. Daluge, Susan Mary; Jurgensen, Cynthia Holder; Martin, Michael Tolar; Osterhout, Martin Howard (Glaxo Group Limited, UK).

PCT Int. Appl. WO 2000009507 A1 20000224, 101 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP5814 19990811. PRIORITY: GB 1998-17623 19980813.

GΙ

$$\mathbb{R}^{4} \text{ (CH2) q1} \xrightarrow{\mathbb{N}} \mathbb{R}^{3} \\ \mathbb{R}^{7} \xrightarrow{\mathbb{N}} \mathbb{N} \\ \mathbb{R}^{7} \xrightarrow{\mathbb{N}} \mathbb{N} \\ \mathbb{R}^{7} \xrightarrow{\mathbb{N}} \mathbb{R}^{2} \\ \mathbb{R}^{7} \xrightarrow{\mathbb{N}} \mathbb{R}^{2} \\ \mathbb{R}^{7} \xrightarrow{\mathbb{N}} \mathbb{R}^{2} \\ \mathbb{R}^{7} \xrightarrow{\mathbb{N}} \mathbb{R}^{7} \\ \mathbb{R}^{7} \xrightarrow{\mathbb{N}} \mathbb{R}^{$$

Title compds. [I; Z = 5-6 membered (substituted) (heteroatom-contg.) cycloalkyl, aryl; R1 = H, Me; R2 = H, alkyl, aryl, aralkyl; m = 0, 1; n = 1-50; X = 0, imino, CH2O, CH2NH, etc.; Q = (CH2)p, (CH:CH)p, (C.tplbond.C)p, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, aminoalkyl; R4, R5 = H, cycloalkyl, alkyl, alkenyl, (substituted) aryl, heterocyclyl; R6, R7 = 0, S; q, q1 = 0-10; with provisos], were prepd. Thus, (E)-4-[1,3-bis(benzyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl]cinnamic acid (prepn. given) in DMF was heated to near reflux and treated with carbonyldimidazole followed by stirring for 18 h to give (E)-1,3-bis(benzyl)-8-[3-[2-(1H-imidazol-1-ylcarbonyl)vinyl]phenyl]-9H-purin-2,6(1H,3H)-dione. The latter was refluxed 20 h with nonaethylene glycol monomethyl ether and K2CO3 in MeCN to give 59% (E)-4-[1,3-bis(benzyl)-1,2,3,6-tetrahydro-2,6-dioxo-9H-purin-8-yl]cinnamic acid nonaethylene glycol Me ether ester. I inhibited adhesion of leukocytes to

endothelial cell monolayers with IC50's of <0.1 nM to >1000 nM.

=> fil caol;s 15 COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL ENTRY SESSION 143.18 143.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL SESSION

CA SUBSCRIBER PRICE

ENTRY SESSION -1.12 -1.12

FILE 'CAOLD' ENTERED AT 09:32:33 ON 02 AUG 2001 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L6 0 L5

=> del his y

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY SESSION 0.31 143.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00 -1.12

FILE 'REGISTRY' ENTERED AT 09:32:44 ON 02 AUG 2001 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 1 AUG 2001 HIGHEST RN 350008-48-9 DICTIONARY FILE UPDATES: 1 AUG 2001 HIGHEST RN 350008-48-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

*** YOU HAVE NEW MAIL ***